Allurion Q3 2024 Earnings Report
Key Takeaways
Allurion Technologies reported a revenue of $5.4 million for Q3 2024, which includes a $1.2 million reduction for product recalled from France. The company is updating its full-year 2024 revenue guidance to between $30 million and $35 million and expects growth in procedure volume to be flat year-over-year. A business restructuring plan is expected to reduce operating expenses by 50% in 2025 and achieve profitability by the end of 2025.
Revenue of $5.4 million, which includes a reduction of $1.2 million for product recalled from France during the third quarter
AI product revenue in the third quarter from the Virtual Care Suite (VCS) grew by 82% versus prior year
Last patient in AUDACITY FDA clinical trial successfully exited, putting top-line readout on track for the end of the year
Initiated business restructuring which is expected to reduce operating expense by 50% in 2025 and achieve profitability by end of 2025
Allurion
Allurion
Forward Guidance
The Company is updating its full-year 2024 revenue guidance to between $30 million and $35 million and expects growth in procedure volume to be flat year-over-year.